Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire☆
Section snippets
Patients
One hundred eleven patients of both sexes with perennial allergic rhinitis, ranging in age from 18 to 50 years (mean ± SD: 31.5 ± 8.8 years), were recruited for the study by 11 allergists and five ear, nose, and throat doctors. To be included, patients had to show clinical evidence of perennial allergic rhinitis, which was investigated through suggestive symptoms (runny nose, itchy nose, sneezing, stuffy nose).
The clinical severity of these symptoms was scored on a 5-point scale ranging from no
Characteristics of the subjects
The demographic characteristics of healthy subjects and patients with rhinitis are shown in Table III. Although the mean ages and the male-to-female ratio were similar in both groups, the patients with rhinitis were significantly more educated than the healthy subjects. The duration of rhinitis ranged from 1 to 25 years (mean ± SD: 7.74 ± 5.78 years). The distribution of scores for each of the four rhinitis symptoms evaluated is presented in Fig. 1. In the rhinitis group 44% of the patients
DISCUSSION
The results of this study show that the SF-36 questionnaire, a generic health-related QOL scale, is sensitive enough to detect the impairments of patients affected by perennial allergic rhinitis in their daily activities and that this questionnaire is reliable in this population. Moreover, this study shows for the first time that perennial allergic rhinitis impairs the QOL of patients with moderate to severe rhinitis compared with healthy subjects.
QOL scales can be divided into generic scales,
Acknowledgements
We thank the following investigators for participating in this study: Dr. Anton (Allergist), Nantes; Dr. Arbez (Occupational doctor), Lyon; Dr. Boachon (ENT), Lyon; Dr. Camuzard (ENT), Nice; Prof. Colas (Allergist), Caluire; Dr. Cosset (Occupational doctor), Nantes; Dr. Dautel (Occupational doctor), Neuville s/Saone; Dr. Ducauchuis (ENT), Nantes; Dr. Durand Perdriel (Allergist), Nantes; Dr. Finet (Occupational doctor), Lyon; Dr. Fleury (Allergist), Lyon; Dr. Fontaine (Occupational doctor),
References (19)
- et al.
The Nottingham Health Profile: subjective health status and medical consultations
Soc Sci Med
(1981) - et al.
Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
Clin Exp Allergy
(1991) - et al.
Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire
Ann Allergy
(1993) - et al.
Quality of Life: assessment and application
Ciba Foundation Symposium
(1987) - et al.
The Sickness Impact Profile: development and final revision of a health status measure
Med Care
(1981) - et al.
The MOS 36-item Short-Form Health Survey (SF-36) I. Conceptual framework and item selection
Med Care
(1992) - et al.
A Short-Form General Health Survey
(1988) - et al.
The MOS 36-item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs
Med Care
(1993) - et al.
Reliability and validity in a patient population
Med Care
(1988)
Cited by (416)
Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study
2023, Journal of Allergy and Clinical Immunology: In PracticeMulti-label rhinitis prediction using ensemble neural network chain with pre-training
2022, Applied Soft ComputingAllergic Rhinitis and Conjunctivitis
2022, Allergy EssentialsClassic test and generalizability theories are both useful for cross-cultural adaptation of an allergic rhinitis health-related quality of life questionnaire
2021, World Allergy Organization JournalRhinitis 2020: A practice parameter update
2020, Journal of Allergy and Clinical ImmunologyAllergy onset and local investor distraction
2018, Journal of Banking and Finance
- ☆
From aServices des Maladies Respiratoires, Hopital Arnaud de Villeneuve, Montpellier; bLudwig Maximilians Universität München, Institut für Medizinische Psychologie Goethestraβe, München; cMAPI, S.A., Lyon; and dUCB S.A., Chemin du Foriest, Braine-l’Alleud, Belgique.